Filing · LD-2 quarterly report
Q3 termination
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Sep 28, 2026
Expenses
$200,000
What this organization spent lobbying with its own staff.
Reported using the LDA's own definitions (method A): the three
LDA methods count different costs, so an expenses figure is
not comparable across filers that used different ones.
Client based in
Virginia
Representation ended
Sep 30, 2026
The registrant reported terminating its work for this client.
Government bodies contacted
2
Lobbying activity
3
Issues related to access to home medical equipment and related reimbursement (i.e., "Diabetes Interventions Addressing Barriers to Enrollment, Technology, and Education Services [DIABETES] Act" (S. 4037) and "DMEPOS Relief Act of 2025" [H.R. 2005, S. 2951]; and competitive bidding, "Supplemental Oxygen Access Reform [SOAR] Act of 2025" [H.R. 2902, S. 1406]); "DME Scammer Prevention (H.R. 8871)"; promoting electronic prescribing platforms; and diabetes management and related durable medical equipment reimbursement channels.
FY 2027 Appropriations.
Issues related to patient access to home medical equipment and related reimbursement.